PerspectiveShould antihistamines be re-considered as antiasthmatic drugs as adjuvants to anti-leukotrienes?
Introduction
In the first half of the 20th Century there was great hope that antihistamines would suppress the symptoms of bronchial asthma and maybe other diseases involving bronchoconstriction or even anaphylaxis. Exogenous histamine induced bronchoconstriction, although with different potencies and efficacies in different animal species, humans showing an intermediate sensitivity. Histamine was detected in tissues and release of an “H-substance” − later that of histamine itself − was detected in the course of anaphylactic or other allergic reactions, from animal and human lungs (see Schild et al., 1951, Sheard et al., 1967, Sheard and Blair, 1970, Piper and Walker, 1973). Mast cells and basophils have been identified as the main source of the release of histamine, as well as other mediators of IgE-mediated reactions. These cell types (especially mast cells) are still considered as protagonists in allergic asthma, especially at its early phase. Considerable progress has been made concerning the way of mast cell activation in the course of antigen-fixed IgE reaction, the release of preformed and freshly-synthesized mediators, as well as other consequences of mast cell activation (for reviews see Holgate, 1999, Nauta et al., 2008, Rivera et al., 2008, Hamid and Tulic, 2009, Weller et al., 2011).
Section snippets
Histamine receptor antagonists
The hopes mentioned above were practically ruined by the very modest usefulness of antihistamines (histamine H1 receptor antagonists) in bronchial asthma, and also in anaphylactic shock; although these antagonists could inhibit the deleterious effects of injected (exogenous) histamine and are effective in milder forms of hypersensitivity reactions, such as hay fever and urticaria.1
Supra-additive relations between mediators
There are several examples of supra-additive interactions, “redundant mechanisms” of mediators (neurotransmitters, local hormones) in the mechanisms of physiological and/or pathopysiological reactions of the body. In such cases, antagonizing one of the mediators may yield no or only minor reduction in the reaction, but inhibiting additional mediators can result in profound inhibition of the process. Even simple addition offers some advantages, first of all, a reduction of dosage of the
Clinico-pharmacological studies with combined antihistamine−anti-leukotriene treatment
Promising human studies have been published with the combination of antihistamines and anti-leukotrienes. The studies were prospective provocation tests performed on a low number of asthmatics. Patients with allergic asthma were challenged with the allergen; bronchoconstriction was inhibited by zafirlukast or, to a lesser extent, by loratadine. Combining the two drugs yielded an approximately additive effect (Roquet et al., 1997). Similarly, a combination of azelastine and montelukast inhibited
Conclusions and the authors' thoughts about future perspectives
This minireview only deals with a special aspect of allergic asthma therapy, i.e., antihistamine–anti-leukotriene combination. Other types of asthma, e.g., exercise-induced bronchoconstriction, are beyond our current topic. We feel that there is ample evidence to justify larger-scale clinical studies with combinations of anti-leulotrienes (receptor antagonists or 5-lipoxygenase inhibitors) and second-generation H1 histamine receptor antagonists in patients with allergic asthma, as already
Acknowledgments
This study was supported by the Hungarian research grants ETT 03–372/2009 (Ministry of Welfare), Grants no. OTKA T-81984, and NK-78059 of Hungarian Research Funds and TÁMOP/ SROP-4.2.2/B-10/1–2010-0029. Experiments on human tissues have been approved by the Regional Research Ethics Committee and the National Research Council Ethics Committee (ETT-TUKEB). The technical contribution of Ms. Veronika Szombati and Mr. Norbert Kasza is gratefully acknowledged.
References (58)
- et al.
Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects
Pulm. Pharmacol.
(1993) Inhaled corticosteroids should be the first line of treatment for children with asthma
Paediatr. Respir. Rev.
(2011)- et al.
Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway
J. Allergy Clin. Immunol.
(1991) - et al.
Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen
J. Allergy Clin. Immunol.
(2005) - et al.
G-protein-dependent activation of mast cell by peptides and basic secretagogues
Peptides
(2002) - et al.
The role of mast cell-derived secreted phospholipases A2 in respiratory allergy
Biochimie
(2010) Recent research and developmental strategy of anti-asthma drugs
Pharmacol. Ther.
(2012)- et al.
Mechanisms of allergy and asthma
Eur. J. Pharmacol.
(2008) Prospects for antihistamines in the treatment of asthma
J. Allergy Clin. Immunol.
(2003)- et al.
Airway smooth muscle and asthma
Allergol. Int.
(2006)
Effects of an H1 blocker, chloropheniramine, on inhalation tests with histamine and allergen in allergic asthma
Chest
New insights on mast cell activation via the high affinity receptor for IgE
Adv. Immunol.
Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus
Life Sci.
Reactions of isolated human asthmatic lung and bronchial tissue to a specific antigen. Histamine release and muscular contraction
Lancet
Role of human basophils and mast cells in the pathogenesis of allergic diseases
J. Allergy Clin. Immunol.
Antagonism of antigen-induced contraction of guinea-pig and human airways
Nature
Efficacy of second-generation antihistamines in patients with allergic rhinitis and comorbid asthma
J. Asthma
Anti-IgE therapy in asthma: rationale and therapeutic potential
Int. Arch. Allergy Immunol.
Pulmonary Pharmacology
The role of the mast cell in allergic bronchospasm
Can. J. Physiol. Pharmacol.
Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective
Curr. Opin. Pulm. Med.
Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma
J. Pharmacol. Exp. Ther.
Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma
Allergy Asthma Proc.
Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4
Proc. Natl. Acad. Sci. USA
Leukotrienes and other eicosanoids as mediators of airway obstruction
Respiration
Studies of the mechanism of passive anaphylaxis in human airway smooth muscle
Can. J. Physiol. Pharmacol.
Single-dose desloratadine and montelukast and allergen-induced late airway responses
Eur. Respir. J.
Summing up 100 years of asthma
Respir. Med.
Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi
Am. J. Respir. Crit. Care Med.
Cited by (7)
Evidence for autocrine and paracrine regulation of allergen-induced mast cell mediator release in the guinea pig airways
2018, European Journal of PharmacologyCitation Excerpt :But epithelium removal is reported to have little effect on allergen-induced histamine and LTC4 release (Undem et al., 1988a, 1988b). Although further work is warranted, these data suggest that H1 receptor antagonists might have opposing influences over immediate hypersensitivity reactions, preventing the end organ effects driven by histamine H1 receptor activation and perhaps working synergistically with cysLT1 receptor antagonists in asthma (Lamm et al., 1984; Roquet et al., 1997; Bartho and Benko, 2013), but also preventing the H1 receptor dependent release of inhibitory prostanoids, an effect that may in turn promote enhanced mast cell degranulation. Thromboxane release and TP receptor activation has also been described during acute responses to allergen in the airways (Schleimer et al., 1987; Krell et al., 1989; Cheng et al., 1990; Ellis et al., 1994; Sundström et al., 2003; Selg et al., 2008; Liu et al., 2012, 2015; Säfholm et al., 2013).
Loss of regulator of G protein signaling 5 promotes airway hyperresponsiveness in the absence of allergic inflammation
2014, Journal of Allergy and Clinical ImmunologyHistamine receptor 2 modifies iNKT cell activity within the inflamed lung
2017, Allergy: European Journal of Allergy and Clinical ImmunologyInternational union of basic and clinical pharmacology. XCVIII. histamine receptors
2015, Pharmacological ReviewsCurrent challenges and perspectives in bronchial asthma therapy
2014, Advances in Respiratory Therapy Research